Literature DB >> 20820948

Subdividing the M1 stage of liver metastasis for nasopharyngeal carcinoma to better predict metastatic survival.

Changchuan Pan1, Ni He, Ming Zhao, Yangkui Gu, Zilin Huang, Wang Li, Yunfei Xia, Peihong Wu.   

Abstract

In nasopharyngeal carcinoma (NPC), the M1 stage of the TNM classification does not differentiate between the site of metastasis or the number of metastatic lesions. However, NPC patients with lung or bone metastases survive longer than do those with liver metastasis (LM). We subdivided the M1 stage of LM to better predict survival in these patients. From the records of 305 NPC patients with LM treated at Sun Yat-sen University Cancer Center between January 2000 and December 2007, we determined the effects of clinical characteristics and the subclassifications of the M1 stage for LM characteristics [the number, size, timing (synchronous vs. metachronous), and distribution of metastases and metastases to other organs] on survival since the diagnosis of LM. Metastatic survival rates were 62% at 1 year, 31% at 2 years, and 21% at 3 years. Having 1-3 metastatic lesions, having lesions less than 5 cm in diameter, and having unilobular LM were better univariate predictors of metastatic survival. Better survival was independently predicted by having one to three (vs. more than three) metastatic lesions (hazards ratio=0.52; 95% CI=0.33-0.82) and unilobular (vs. bilobular) lesions (hazards ratio=0.35; 95% CI=0.22-0.57). The current report constitutes large samples of LM from NPC from our single institution with correlation between LM characteristics and metastatic survival. Patients with NPC and one to three liver metastases or unilobular metastases survive longer than their counterparts, and aggressive treatment should be considered.

Entities:  

Mesh:

Year:  2010        PMID: 20820948     DOI: 10.1007/s12032-010-9643-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  19 in total

1.  Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation.

Authors:  P Rodrigus; P de Brouwer; E Raaymakers
Journal:  Lung Cancer       Date:  2001-05       Impact factor: 5.705

2.  Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure.

Authors:  A W Lee; Y F Poon; W Foo; S C Law; F K Cheung; D K Chan; S Y Tung; M Thaw; J H Ho
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

3.  Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival.

Authors:  F B Geara; G Sanguineti; S L Tucker; A S Garden; K K Ang; W H Morrison; L J Peters
Journal:  Radiother Oncol       Date:  1997-04       Impact factor: 6.280

4.  Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials.

Authors:  S H Cheng; K L Yen; J J Jian; S Y Tsai; N M Chu; S Y Leu; K Y Chan; T D Tan; J C Cheng; C Y Hsieh; A T Huang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-01       Impact factor: 7.038

5.  [Prognosis analysis of nasopharyngeal carcinoma patients with distant metastasis].

Authors:  Cheng-Tao Wang; Ka-Jia Cao; Yin Li; Guo-Feng Xie; Pei-Yu Huang
Journal:  Ai Zheng       Date:  2007-02

6.  Clinical features and management of distant metastases of nasopharyngeal carcinoma.

Authors:  S F Leung; P M Teo; W W Shiu; S Y Tsao; T W Leung
Journal:  J Otolaryngol       Date:  1991-02

7.  Surgical resection of a solitary liver metastasis from nasopharyngeal carcinoma: a case report.

Authors:  Spiros Delis; Ioannis Biliatis; Antonia Bourli; Nikolaos Kapranos; Christos Dervenis
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2006-11

8.  Design of a prognostic index score for metastatic nasopharyngeal carcinoma.

Authors:  Y K Ong; D M Heng; B Chung; S S Leong; J Wee; K W Fong; T Tan; E H Tan
Journal:  Eur J Cancer       Date:  2003-07       Impact factor: 9.162

9.  Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation.

Authors:  A R Gillams; W R Lees
Journal:  Eur Radiol       Date:  2009-01-10       Impact factor: 5.315

Review 10.  The process for continuous improvement of the TNM classification.

Authors:  Mary K Gospodarowicz; Daniel Miller; Patti A Groome; Frederick L Greene; Pamela A Logan; Leslie H Sobin
Journal:  Cancer       Date:  2004-01-01       Impact factor: 6.860

View more
  17 in total

1.  M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma.

Authors:  Lujun Shen; Jun Dong; Sheng Li; Yue Wang; Annan Dong; Wanhong Shu; Ming Wu; Changchuan Pan; Yunfei Xia; Peihong Wu
Journal:  Oncologist       Date:  2015-02-06

2.  Comparative serum proteomic analysis involving liver organ-specific metastasis-associated proteins of nasopharyngeal carcinoma.

Authors:  Changchuan Pan; Yalan Tao; Ming Zhao; Wang Li; Zilin Huang; Jing Gao; Yanhen Wu; Jingrui Yu; Peihong Wu; Yunfei Xia; Jin Lu
Journal:  Exp Ther Med       Date:  2012-03-23       Impact factor: 2.447

3.  Prognostic stratification of patients with metastatic nasopharyngeal carcinoma using a clinical and biochemical scoring system.

Authors:  Jeremy Chee; Kwok Seng Loh; Ivan Tham; Francis Ho; Lea Choung Wong; Chee Seng Tan; Boon Cher Goh; Chwee Ming Lim
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-28       Impact factor: 4.553

4.  Selected reaction monitoring for colorectal cancer diagnosis using a set of five serum peptides identified by BLOTCHIP®-MS analysis.

Authors:  Kazuhiko Uchiyama; Yuji Naito; Nobuaki Yagi; Katsura Mizushima; Yasuki Higashimura; Yasuko Hirai; Osamu Dohi; Tetsuya Okayama; Naohisa Yoshida; Kazuhiro Katada; Kazuhiro Kamada; Osamu Handa; Takeshi Ishikawa; Tomohisa Takagi; Hideyuki Konishi; Daisuke Nonaka; Kyoichi Asada; Lyang-Ja Lee; Kenji Tanaka; Yoshiaki Kuriu; Masayoshi Nakanishi; Eigo Otsuji; Yoshito Itoh
Journal:  J Gastroenterol       Date:  2018-03-01       Impact factor: 7.527

5.  Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective study.

Authors:  Meng-Xia Zhang; Ting Liu; Rui You; Xiong Zou; Yong-Long Liu; Xi Ding; Chong-Yang Duan; Han-Shi Xu; You-Ping Liu; Rou Jiang; Zhi-Qiang Wang; Chao Lin; Yu-Long Xie; Si-Yuan Chen; Yan-Feng Ouyang; Ruo-Qi Xie; Yi-Jun Hua; Rui Sun; Pei-Yu Huang; Shun-Lan Wang; Ming-Yuan Chen
Journal:  Ther Adv Med Oncol       Date:  2022-07-15       Impact factor: 5.485

6.  Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: A study of 1027 cases and review of the literature.

Authors:  Chang-Chuan Pan; Jin Lu; Jing-Rui Yu; Ping Chen; Wang Li; Zi-Lin Huang; Ming Zhao; Zhi-Mei Huang; Yun-Fei Xia; Yan-Hen Wu; Pei-Hong Wu
Journal:  Exp Ther Med       Date:  2012-05-21       Impact factor: 2.447

7.  Identification alpha-2-HS-glycoprotein precursor and tubulin beta chain as serology diagnosis biomarker of colorectal cancer.

Authors:  Nai-jun Fan; Rui Kang; Xue-yan Ge; Ming Li; Yan Liu; Hong-mei Chen; Chun-fang Gao
Journal:  Diagn Pathol       Date:  2014-03-12       Impact factor: 2.644

8.  Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis.

Authors:  Ming-Yuan Chen; Rou Jiang; Ling Guo; Xiong Zou; Qing Liu; Rui Sun; Fang Qiu; Zhong-Jun Xia; Hui-Qiang Huang; Li Zhang; Ming-Huang Hong; Hai-Qiang Mai; Chao-Nan Qian
Journal:  Chin J Cancer       Date:  2013-11

9.  Subdivision of M category for nasopharyngeal carcinoma with synchronous metastasis: time to expand the M categorization system.

Authors:  Lu-Jun Shen; Si-Yang Wang; Guo-Feng Xie; Qi Zeng; Chen Chen; An-Nan Dong; Zhi-Mei Huang; Chang-Chuan Pan; Yun-Fei Xia; Pei-Hong Wu
Journal:  Chin J Cancer       Date:  2015-08-12

10.  Efficacy of minimally invasive therapies on unresectable pancreatic cancer.

Authors:  Zhi-Mei Huang; Chang-Chuan Pan; Pei-Hong Wu; Ming Zhao; Wang Li; Zi-Lin Huang; Rui-Yang Yi
Journal:  Chin J Cancer       Date:  2012-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.